One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
NeuroOne Medical Technologies Corporation
NMTC · NCM · Healthcare · Medical Devices
Current price
$0.78
52-week range
$0.75 - $6.12
Market cap
$7.08M
Balance sheet
Healthy
-12.65x Concerning
Net cash $1.87M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 9.9% last year.
- Risk Return on equity was -124.7% last year — the company lost money on shareholders' equity.
What this company does
NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation makes special medical devices used by doctors to record brain activity for patients with conditions like epilepsy. Their main income comes from selling these devices, and this is important because it shows how much money they are making from their core business activities after covering the costs of making and selling their products, a measure of their profitability.
How the company got here
NeuroOne Medical Technologies Corporation, established in 2009, emerged from pioneering research conducted at the Mayo Clinic and the University of Wisconsin. [5, 7, 14] The company's journey has been marked by the development and FDA clearance of its innovative thin-film electrode technology, designed to improve the diagnosis and treatment of neurological disorders. [4, 6, 9] Key collaborations, such as the one with the University of Minnesota Medical School for epilepsy research, have further propelled its advancements. [8] NeuroOne has also focused on strengthening its financial position through successful capital raises and has demonstrated significant revenue growth and improving gross margins in recent financial reporting periods. [11]
What it actually does
NeuroOne Medical Technologies develops and commercializes minimally invasive medical devices that help diagnose and treat neurological conditions. [2, 9] Their core technology involves ultra-thin, flexible electrodes that can be used for a variety of functions, including monitoring brain activity, mapping brain regions, recording electrical signals, and performing therapeutic ablation (the removal or destruction of tissue). [7] These solutions aim to improve patient outcomes, reduce hospitalizations, and lower healthcare costs for conditions like epilepsy, Parkinson's disease, and chronic pain. [2, 4, 6]
Evo Cortical Electrodes
This business line focuses on high-resolution, flexible thin-film electrodes designed for temporary use (less than 30 days) on the surface of the brain during electrocorticography (ECoG) or intracranial EEG surgeries. [1, 3] These electrodes are engineered to minimize the body's immune response and enhance surgical handling, ultimately aiming to improve surgical outcomes. [1, 3] They are used for recording brain activity and are a key diagnostic tool.
Evo sEEG Electrodes
This segment involves advanced diagnostic electrodes for seizure detection, also designed for temporary use (less than 30 days). [1, 3] The Evo sEEG (stereoelectroencephalography) electrodes are characterized by their high accuracy in placement and signal quality, which are crucial for precise diagnosis and effective treatment planning for patients with neurological disorders. [3]
OneRF Ablation System
This is NeuroOne's radiofrequency ablation system, which has received FDA clearance. [1, 3, 4] It's designed to provide bedside monitoring, mapping, and therapeutic ablation for patients, particularly those with epilepsy. [3] The system integrates diagnostic and therapeutic capabilities, allowing for lesion creation in nervous tissue. [1] This technology aims to offer a less invasive option for treatment and streamline the procedural workflow for physicians. [6]
OneRF Trigeminal Nerve Ablation System
This specific product line is an extension of the OneRF platform, FDA-cleared for creating radiofrequency lesions to treat pain, specifically trigeminal neuralgia (a condition causing facial pain), and for other functional neurosurgical procedures. [4, 6] It leverages the company's proprietary radiofrequency ablation technology and is designed to support a more streamlined procedural workflow. [6]
Drug Delivery and Other Neuromodulation Programs
NeuroOne is actively developing other applications for its technology platform. [2, 11] This includes a drug delivery system using sEEG electrodes, for which they have received an initial order for preclinical research. [11] Additionally, the company is exploring spinal cord stimulation and basivertebral nerve ablation for chronic low back pain. [6, 11] These programs represent potential new markets and applications for NeuroOne's core electrode technology.
What management is betting on now
NeuroOne's management is focused on expanding the commercialization of its existing FDA-cleared products, particularly the OneRF Ablation System and the OneRF Trigeminal Nerve Ablation System. [6, 11] They are also heavily invested in advancing their development programs, especially the sEEG-based drug delivery system and exploring applications in spinal cord stimulation and pain management. [11] The strategy emphasizes leveraging their versatile electrode technology platform across multiple neurological disorders and pain indications, aiming for disciplined growth, improved financial performance (like increasing gross margins), and reaching profitability while minimizing shareholder dilution. [7, 11]
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-2.70M
FY2025 Q1
$183.63K
FY2025 Q2
$-59.31K
FY2025 Q3
$-1.51M
FY2025 Q4
$-1.54M
FY2026 Q1
$-3.16M
FY2026 Q2
$-1.37M
FY2026 Q3
$-1.10M
Revenue
$1.97M
Net income
$-2.01M
Diluted EPS
-0.28
Operating cash flow
$-1.08M
Free cash flow
$-1.10M
Fetching…
Sources
Revenue
$2.39M
Net income
$-2.09M
Diluted EPS
-0.25
Operating cash flow
$-1.33M
Free cash flow
$-1.37M
Fetching…
Sources
Revenue
$2.89M
Net income
$-1.44M
Diluted EPS
-0.03
Operating cash flow
$-3.12M
Free cash flow
$-3.16M
Fetching…
Sources
Revenue
$2.74M
Net income
$-1.62M
Diluted EPS
-0.05
Operating cash flow
$-1.53M
Free cash flow
$-1.54M
Fetching…
Sources
Revenue
$1.70M
Net income
$-1.50M
Diluted EPS
-0.03
Operating cash flow
$-1.46M
Free cash flow
$-1.51M
Fetching…
Sources
Revenue
$1.39M
Net income
$-2.27M
Diluted EPS
-0.07
Operating cash flow
$-56.14K
Free cash flow
$-59.31K
Fetching…
Sources
Revenue
$3.27M
Net income
$1.79M
Diluted EPS
0.06
Operating cash flow
$208.05K
Free cash flow
$183.63K
Fetching…
Sources
Revenue
$272.28K
Net income
$-3.35M
Diluted EPS
-0.11
Operating cash flow
$-2.67M
Free cash flow
$-2.70M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.78
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $1.9M - more cash than debt. Interest coverage -12.7x.
Net debt
$-1.87M
Interest coverage
-12.65x
NeuroOne Medical Technologies Corporation's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here.
Healthy
Worse cushion
Baseline
Better cushion
NMTC
BASELINE
NeuroOne Medical Technologies Corporation
Total debt $175.34K Interest coverage -12.65x This is the baseline the peer rows are being compared against.
Total debt $28.15B Interest coverage 9.55x This peer still has a real interest-payment cushion, while NMTC does not.
Total debt $0.00 Interest coverage 8.05x This peer still has a real interest-payment cushion, while NMTC does not.
Total debt $11.95B Interest coverage 11.38x This peer still has a real interest-payment cushion, while NMTC does not.
Total debt $15.43B Interest coverage 8.33x This peer still has a real interest-payment cushion, while NMTC does not.
Total debt $31.44B Interest coverage 16.33x This peer still has a real interest-payment cushion, while NMTC does not.
What you should know
The case for and against NMTC
1 Reward
1 Risk
Rewards
-
Revenue grew 9.9% last year.
Risks
-
Return on equity was -124.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-2.78x
P/B
1.79x
P/S
0.57x
EV/EBITDA
-0.81x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
23.0%
Operating margin
-122.9%
Net margin
-59.7%
ROE
-124.7%
ROA
-58.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.05x
Current ratio
2.84x
Quick ratio
1.54x
Total debt
$175.34K
Total cash
$2.05M
Growth
How the business has been compounding
Revenue TTM
$10.00M
Revenue 5Y CAGR
167.3%
EPS TTM
-0.99
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-7.05M
Free CF TTM
$-2.92M
FCF margin
-29.2%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—